NI200900084A - Compuestos de pirazol y triazol sustituidos como inhibidores de ksp. - Google Patents

Compuestos de pirazol y triazol sustituidos como inhibidores de ksp.

Info

Publication number
NI200900084A
NI200900084A NI200900084A NI200900084A NI200900084A NI 200900084 A NI200900084 A NI 200900084A NI 200900084 A NI200900084 A NI 200900084A NI 200900084 A NI200900084 A NI 200900084A NI 200900084 A NI200900084 A NI 200900084A
Authority
NI
Nicaragua
Prior art keywords
pirazole
triazole compounds
compounds substituted
ksp inhibitors
pharmaceutically acceptable
Prior art date
Application number
NI200900084A
Other languages
English (en)
Inventor
Xia Yi
G Mendenhall Kris
A Barsanti Paul
O Walter Annette
Duhl David
A Renhowe Paul
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NI200900084A publication Critical patent/NI200900084A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Se dan a conocer nuevos compuestos de pirazol y triazol sustituidos de la fórmula (I), y sales farmacéuticamente aceptables, ésteres o pro-fármacos de los mismos, composiciones de los derivados junto con vehículos farmacéuticamente aceptables, y usos de los mismos.
NI200900084A 2006-11-13 2009-05-13 Compuestos de pirazol y triazol sustituidos como inhibidores de ksp. NI200900084A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85896406P 2006-11-13 2006-11-13

Publications (1)

Publication Number Publication Date
NI200900084A true NI200900084A (es) 2010-01-29

Family

ID=39144618

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200900084A NI200900084A (es) 2006-11-13 2009-05-13 Compuestos de pirazol y triazol sustituidos como inhibidores de ksp.

Country Status (32)

Country Link
US (2) US8129358B2 (es)
EP (1) EP2091926B1 (es)
JP (1) JP5264755B2 (es)
KR (1) KR20090081020A (es)
CN (1) CN101558049B (es)
AR (1) AR063805A1 (es)
AU (1) AU2007323998B2 (es)
BR (1) BRPI0719002A2 (es)
CA (1) CA2668661A1 (es)
CL (1) CL2007003272A1 (es)
CO (1) CO6382171A2 (es)
CR (1) CR10787A (es)
DO (1) DOP2009000106A (es)
EA (1) EA017748B1 (es)
EC (1) ECSP099326A (es)
ES (1) ES2557478T3 (es)
GE (1) GEP20125389B (es)
GT (1) GT200900122A (es)
HN (1) HN2009000968A (es)
IL (1) IL198471A0 (es)
MA (1) MA30959B1 (es)
MX (1) MX2009005071A (es)
NI (1) NI200900084A (es)
NO (1) NO20092226L (es)
NZ (1) NZ576640A (es)
PE (1) PE20081169A1 (es)
SM (1) SMP200900045B (es)
TN (1) TN2009000178A1 (es)
TW (1) TW200831480A (es)
UA (1) UA97256C2 (es)
WO (1) WO2008063912A1 (es)
ZA (1) ZA200902940B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090081020A (ko) * 2006-11-13 2009-07-27 노파르티스 아게 Ｋｓｐ 억제제로서의 치환된 피라졸 및 트리아졸 화합물
MX2009007260A (es) * 2007-01-05 2009-07-10 Novartis Ag Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5).
MX2012011910A (es) * 2010-04-15 2012-11-29 Novartis Ag Compuestos de triazol como inhibidores de ksp.
US8748626B2 (en) 2010-04-15 2014-06-10 Novartis Ag Oxazole and thiazole compounds as KSP inhibitors
CA2892919A1 (en) * 2012-12-05 2014-06-12 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
WO2014151030A1 (en) * 2013-03-15 2014-09-25 Novartis Ag Cell proliferation inhibitors and conjugates thereof
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
WO2015084763A2 (en) 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
US20190161499A1 (en) * 2015-12-11 2019-05-30 Syngenta Participations Ag Pesticidally active 1,2,4-triazole derivatives
WO2021138540A1 (en) 2020-01-03 2021-07-08 Berg Llc Polycyclic amides as ube2k modulators for treating cancer

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5011472A (en) * 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5185450A (en) * 1991-02-19 1993-02-09 University Of South Florida Tetrazolium compounds for cell viability assays
AUPP042397A0 (en) * 1997-11-18 1997-12-11 Fujisawa Pharmaceutical Co., Ltd. 5-arylpyrazole compounds
EP1165519A1 (en) 1999-04-02 2002-01-02 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
CN100381428C (zh) 1999-10-27 2008-04-16 赛特凯恩蒂克公司 喹唑啉酮类化合物及应用
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
CA2425185A1 (en) 2000-10-06 2002-04-11 Stephane De Lombaert Benzimidazole and indole derivatives as crf receptor modulators
EP1351671A1 (en) 2001-01-19 2003-10-15 Cytokinetics, Inc. Triphenylmethane kinesin inhibitors
WO2002057244A1 (en) 2001-01-19 2002-07-25 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
US7060705B2 (en) 2001-11-07 2006-06-13 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003039480A2 (en) 2001-11-08 2003-05-15 The University Of Chicago Method of treating disorder related to high cholesterol concentration
WO2003043995A1 (en) 2001-11-20 2003-05-30 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
DE60222302T2 (de) 2001-12-06 2008-05-29 Merck & Co., Inc. Inhibitoren von mitotischem kinesin
AU2002357043B2 (en) 2001-12-06 2008-04-24 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
JP2005515208A (ja) 2001-12-06 2005-05-26 メルク　エンド　カムパニー　インコーポレーテッド 有糸***性キネシン阻害剤
US7262187B2 (en) 2001-12-06 2007-08-28 Merck & Co., Inc. Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor
US7262186B2 (en) 2001-12-06 2007-08-28 Merck & Co., Inc. Substituted pyrazolo[3,4-d] pyrimidinones as a mitotic kinesin inhibitor
CA2468794A1 (en) * 2001-12-07 2003-06-19 Virginia Commonwealth University Treatment of neoplasia
CA2472470A1 (en) 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
EP1480980A4 (en) 2002-02-15 2005-04-20 Cytokinetics Inc SYNTHESIS OF QUINAZOLINONES
WO2003079973A2 (en) 2002-03-08 2003-10-02 Merck & Co., Inc. Mitotic kinesin inhibitors
BR0309892A2 (pt) 2002-05-09 2011-04-05 Cytokinetics Inc composto, composição, métodos para modular a atividade da cinesina de ksp, para inibir a ksp, e para o tratamento de uma doença proliferativa celular, e, uso de um composto
US7214800B2 (en) 2002-05-09 2007-05-08 Cytokinetics, Inc. Compounds, compositions, and methods
US20040053948A1 (en) 2002-05-10 2004-03-18 Cytokinetics, Inc. Compounds, compositions and methods
JP2005536475A (ja) 2002-05-23 2005-12-02 サイトキネティクス・インコーポレーテッド 化合物、組成物、および方法
AU2003231799A1 (en) 2002-05-23 2003-12-12 Merck & Co., Inc. Mitotic kinesin inhibitors
IL165624A0 (en) 2002-06-14 2006-01-15 Merck & Co Inc Mitotic kinesin inhibitors
EP1515949B1 (en) 2002-06-14 2007-03-14 Merck & Co., Inc. Mitotic kinesin inhibitors
GB0214139D0 (en) * 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
US20060134767A1 (en) 2002-07-08 2006-06-22 Buser-Doepner Carolyn A Mitotic kinesin binding site
DE60326248D1 (de) 2002-07-17 2009-04-02 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
EP1537089A4 (en) 2002-07-23 2008-04-16 Cytokinetics Inc CONNECTIONS, COMPOSITIONS AND PROCEDURES
US20040048853A1 (en) 2002-08-21 2004-03-11 Gustave Bergnes Compounds, compositions, and methods
EP1554265A4 (en) 2002-09-13 2008-05-07 Cytokinetics Inc COMPOSITIONS, COMPOSITIONS AND M THODES
US20080021079A1 (en) 2003-05-07 2008-01-24 Han-Jie Zhou Compounds, Compositions, and Methods
WO2004103282A2 (en) 2003-05-15 2004-12-02 Cytokinetics, Inc. Compounds, compositions and methods
EP1732926B1 (en) 2004-04-06 2008-12-31 Novartis Vaccines and Diagnostics, Inc. Mitotic kinesin inhibitors
EP1753723B1 (en) * 2004-05-21 2008-08-13 Novartis Vaccines and Diagnostics, Inc. Substituted quinoline derivatives as mitotic kinesin inhibitors
KR101170925B1 (ko) 2004-06-18 2012-08-07 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 암 치료용 키네신 방추 단백질 (ｋｓｐ) 억제제로서의ｎ-(1-(1-벤질-4-페닐-1ｈ-이미다졸-2-일)-2,2-디메틸프로필)벤자미드 유도체 및 관련 화합물
JP2008517057A (ja) * 2004-10-19 2008-05-22 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド インドールおよびベンゾイミダゾール誘導体
US7829589B2 (en) 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
MY147188A (en) 2005-08-09 2012-11-14 Novartis Ag Substituted imidazole compounds as ksp inhibitors
KR20090081020A (ko) * 2006-11-13 2009-07-27 노파르티스 아게 Ｋｓｐ 억제제로서의 치환된 피라졸 및 트리아졸 화합물

Also Published As

Publication number Publication date
CR10787A (es) 2009-07-02
AU2007323998B2 (en) 2011-09-22
KR20090081020A (ko) 2009-07-27
UA97256C2 (ru) 2012-01-25
BRPI0719002A2 (pt) 2013-12-17
US20100034813A1 (en) 2010-02-11
ES2557478T3 (es) 2016-01-26
AU2007323998A1 (en) 2008-05-29
TN2009000178A1 (en) 2010-10-18
ECSP099326A (es) 2009-06-30
CN101558049B (zh) 2012-08-15
WO2008063912A1 (en) 2008-05-29
SMAP200900045A (it) 2009-07-14
EP2091926A1 (en) 2009-08-26
CL2007003272A1 (es) 2008-03-24
NO20092226L (no) 2009-08-12
CA2668661A1 (en) 2008-05-29
EA017748B1 (ru) 2013-02-28
JP2010509365A (ja) 2010-03-25
DOP2009000106A (es) 2009-05-31
CN101558049A (zh) 2009-10-14
AR063805A1 (es) 2009-02-18
MA30959B1 (fr) 2009-12-01
EA200900631A1 (ru) 2009-12-30
EP2091926B1 (en) 2015-10-21
CO6382171A2 (es) 2012-02-15
ZA200902940B (en) 2010-05-26
GEP20125389B (en) 2012-01-25
NZ576640A (en) 2011-10-28
SMP200900045B (it) 2010-03-01
US7902240B2 (en) 2011-03-08
US20080200462A1 (en) 2008-08-21
JP5264755B2 (ja) 2013-08-14
IL198471A0 (en) 2010-02-17
US8129358B2 (en) 2012-03-06
HN2009000968A (es) 2011-10-25
PE20081169A1 (es) 2008-09-24
GT200900122A (es) 2011-09-14
MX2009005071A (es) 2009-05-25
TW200831480A (en) 2008-08-01

Similar Documents

Publication Publication Date Title
NI200900084A (es) Compuestos de pirazol y triazol sustituidos como inhibidores de ksp.
DOP2009000169A (es) Derivados ciclados como inhibidores de eg-5
CR20140215A (es) Ciclopenta (d) pirimidinas como inhibidores de la proteina cinasa akt
TN2010000052A1 (fr) Derives de pyrazole et leur utilisation comme inhibiteurs de raf
ECSP10010272A (es) Derivados bis-(sulfonilamino) para uso en terapia
CU23834B1 (es) Compuestos de pirazolo [3,4-d] pirimidinona y sus derivados para la inhibición pde9
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
AR062745A1 (es) 2-[4-(7-etil-5h-pirrolo[2,3-b]pirazin-6-il)-fenil]-propan-2-ol como inhibidor de quinasa
NI201000085A (es) Derivados bis - (sulfonilamino) en terapia 066.
ECSP088549A (es) Nuevos derivados de pirrol fusionado
TW200612958A (en) Substituted imidazole derivatives
CR11229A (es) Pirimidil ciclopentanos como inhibidores de proteina cinasa akt
UY31189A1 (es) Compuestos heterocíclicos
TW200800951A (en) Substituted imidazole compounds as KSP inhibitors
ECSP055729A (es) Nuevos inhibidores biciclicos de la lipasa sensible a hormonas
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
ATE519764T1 (de) Spiroindolinon-derivate
SV2011003916A (es) Nuevas lactamas como inhibidores de beta secretasa
AR057885A1 (es) Acido 1-(1-(2- etoxietil) - 1- etil-7-(4- metilpiridin -2- ilamino)- 1h pirazolo (4,3-d) pirimidin -5- il) piperidina -4- carboxilico y las sales del mismo. composiciones farmaceuticas.
GT200800296A (es) Derivados de ácido fenilacético
AR061740A1 (es) Nuevos derivados naftalenicos, su procedimiento de praparacion y las composiciones farmaceuticas que los contienen
CU20100125A7 (es) Derivados bis-(sulfonilamino) para uso en terapia
CU20090115A7 (es) Derivados de imidazol como inhibidores de proteína de huso de cinesina (eg-5)